阿贝西利(Abemaciclib) - 药物靶点：CDK4 x CDK6_在研适应症：晚期乳腺癌，转移性乳腺癌，HR阳性HER2阴性淋巴结阳性乳腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Abemaciclib (JAN/USAN)、Abemaciclib mesylate、Bemaciclib

+ [8]

靶点

CDK4 x CDK6

作用方式

抑制剂

作用机制

CDK4抑制剂(细胞周期蛋白依赖性激酶4抑制剂)、CDK6抑制剂(细胞周期蛋白依赖性激酶6抑制剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病呼吸系统疾病+ [7]

在研适应症

晚期乳腺癌转移性乳腺癌HR阳性HER2阴性淋巴结阳性乳腺癌+ [77]

非在研适应症

原研机构

在研机构

+ [17]

非在研机构

Zeno Alpha, Inc.

Veru, Inc.

权益机构

Agilent Technologies, Inc.

Sermonix Pharmaceuticals LLC

Veru, Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2017-09-28),

HR阳性/HER2阴性乳腺癌

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、优先审评 (中国)、特殊审批 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C27H32F2N8

InChIKeyUZWDCWONPYILKI-UHFFFAOYSA-N

CAS号1231929-97-7

关联

256

项与阿贝西利相关的临床试验

NCT07191717

/ Not yet recruiting临床2期IIT

Phase II Minimal Residual Disease Study of Selective Estrogen Receptor Degrader Imlunestrant With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib in Patients With ER+ Breast Cancer (MIRI)

This phase II trial studies how well imlunestrant and abemaciclib work in treating patients with estrogen receptor positive (ER+) breast cancer who have tumor remaining in the blood following treatment (minimal residual disease). Estrogen can cause the growth of breast cancer cells. Imlunestrant lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Imlunestrant and abemaciclib may be effective in treating patients with ER+ breast cancer who have minimal residual disease.

开始日期2026-04-30

申办/合作机构

Jonsson Comprehensive Cancer Center

NCT06498648

/ Recruiting临床1/2期IIT

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with leiomyosarcoma or dedifferentiated liposarcoma (phase 2). Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Giving abemaciclib with gemcitabine may be safe and effective when compared to treatment with gemcitabine and docetaxel for patients with advanced or metastatic soft tissue sarcoma or leiomyosarcoma or dedifferentiated liposarcoma.

开始日期2026-04-12

申办/合作机构

National Cancer Institute

NCT07292207

/ Not yet recruiting临床2期IIT

Phase 2 Study of Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

The goal of this clinical study is to determine whether monitoring ctDNA and treating patients who become ctDNA-positive with abemaciclib can help prevent the recurrence of hormone receptor-positive, HER2-negative breast cancer after curative surgery and standard therapy. The study will also assess the safety of abemaciclib and the medical problems that may occur during treatment. Participants will receive routine follow-up after surgery, undergo regular blood tests to measure ctDNA, and, if ctDNA becomes positive, receive abemaciclib for a defined treatment period with scheduled clinic visits for examinations and safety assessments. Researchers will evaluate recurrence-free survival, distant recurrence-free survival, adverse events, the time between ctDNA positivity and clinical recurrence, and the rate of ctDNA clearance at the end of abemaciclib therapy.

开始日期2026-01-10

申办/合作机构

Nagoya City University

[+5]

100 项与阿贝西利相关的临床结果

登录后查看更多信息

100 项与阿贝西利相关的转化医学

登录后查看更多信息

100 项与阿贝西利相关的专利（医药）

登录后查看更多信息

1,358

项与阿贝西利相关的文献（医药）

2026-02-01·BREAST

How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: balancing oncologic benefit and surgical safety

Article

作者: Cazenave, Michel Gabriel ; Benoit, Louise ; Bonneau, Claire ; Ammendola, Ornella ; Mahiou, Katia ; Elahi, Leslie

Abemaciclib, a CDK4/6 inhibitor, has emerged as a pivotal therapy in hormone receptor-positive, HER2-negative breast cancer, including in the adjuvant setting for high-risk early disease. Its integration into long-term oncologic strategies poses new challenges for peri-operative management, particularly in the context of secondary breast reconstruction. Preclinical studies suggest impaired wound healing potential, while clinical data highlight an increased risk of venous thromboembolism. No study to date has specifically addressed surgical outcomes under abemaciclib therapy. We call for the need of a clinical trial in abemaciclib perioperative management and propose pragmatic peri-operative strategies to optimize patient safety without compromising oncologic benefit.

2026-02-01·BREAST

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Article

作者: Lipiec, Paulina ; Kiszka, Joanna ; Żubrowska, Justyna ; Bieńkowski, Michał ; Danielewicz, Iwona ; Kustra, Ewa ; Szymanowski, Bartosz ; Pogoda, Katarzyna ; Czartoryska-Arłukowicz, Bogumiła ; Bałata, Anna ; Lewandowski, Tomasz ; Łobaza, Magdalena ; Sobocki, Bartosz K ; Szymanik-Resko, Magdalena ; Hudała-Klecha, Joanna ; Winsko-Szczęsnowicz, Karolina ; Tomasik, Bartłomiej ; Koriat-Błońska, Anna ; Kalinka, Ewa ; Jurczyk, Michał ; Kowalewska-Felczak, Agnieszka ; Grela-Wojewoda, Aleksandra ; Szwiec, Marek ; Łacko, Aleksandra ; Soter, Katarzyna ; Ziobro, Marek ; Duchnowska, Renata ; Kade, Grzegorz ; Myśliwiec, Paulina ; Streb, Joanna ; Radecka, Barbara ; Ramlau, Rodryg ; Jassem, Jacek ; Smok-Kalwat, Jolanta ; Litwiniuk, Maria

BACKGROUND:

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first- and second-line treatments for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Real-world data (RWD) may inform the optimal use of these agents in routine practice.

PATIENTS AND METHODS:

The multicenter, population-based POLiCDK study compared progression-free survival (PFS), second PFS, and overall survival (OS) in ABC patients with HR+/HER2- ABC treated with palbociclib (PAL), ribociclib (RIB), or abemaciclib (ABE) in first- or second-line ET settings at 16 Polish centers between September 2017 and January 2025. Analyses were stratified by endocrine sensitivity/resistance, and stabilized inverse probability of treatment weighting was used to balance baseline characteristics.

RESULTS:

Among 2063 patients (701 PAL, 968 RIB, 394 ABE), 1583 (76.7 %) received CDK4/6i in the first-line and 480 (23.3 %) in the second-line setting. Overall, 927 (44.9 %) had de novo ABC; 819 (39.7 %) were endocrine-naïve, 158 (8.9 %) primary resistant, and 808 (39.2 %) secondary resistant. Median follow-up was 35.9, 24.1, and 21.4 months for PAL, RIB, and ABE, respectively. In endocrine-naïve patients, PFS did not differ significantly between CDK4/6i combined with aromatase inhibitors (AIs). In secondary endocrine-resistant disease, RIB and ABE outperformed PAL with AI combinations, whereas outcomes with fulvestrant were similar. In second-line therapy, all three CDK4/6i showed comparable results. Adjusted hazard ratios confirmed these trends without consistent superiority of any single agent.

CONCLUSIONS:

Endocrine sensitivity/resistance and ET partner were major determinants of outcome with CDK4/6i plus ET in HR+/HER2- ABC, informing individualized treatment selection and sequencing.

2026-02-01·JOURNAL OF NEUROVIROLOGY

A report of progressive multifocal leukoencephalopathy during adjuvant abemaciclib for breast cancer

Article

作者: Caffo, Orazio ; Peterlana, Dimitri ; Borras-Ferreres, Ricard ; Segatta, Francesca

Drugs inhibiting the cyclin-dependent kinases (CDK) 4 and 6 are widely used for the treatment of luminal breast cancer, in the adjuvant and in the metastatic setting, and adverse events are well-known. Progressive multifocal leukoencephalopathy (PML) is classically linked to immunosuppression. We present a case of progressive multifocal leukoencephalopathy that developed during adjuvant abemaciclib therapy in a seventy-year-old woman diagnosed with locally advanced ductal carcinoma of the breast. Neurological impairment developed after 18 months of initiating abemaciclib and in imaging tests a left frontal brain lesion appeared. Metastasis was excluded and the evidence of the John Cunningham polyomavirus (JCPyV) genome, both in the blood and in the cerebrospinal fluid, supported the diagnosis of PML. We did not identify significant immune blood cell counts alterations, nor other causes of immunosuppression; the patient was not treated with other immunosuppressive drugs. We speculate that different immune mechanism alterations related to abemaciclib, which has a high penetration rate in the brain, may be involved in an increased risk of JCPyV reactivation and consequently PML development.

1,093

项与阿贝西利相关的新闻（医药）

2026-01-28

·蒲公英Ouryao

参比制剂（第101批）名单发布

转自：国家药监局编辑：随风 2026年01月28日，国家药监局发布了第101批次仿制药一致性评价参比制剂目录，新增品种28个。经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第一百零一批）。新增品种：甲磺酸加诺沙星片、甲磺酸兰泽替尼片、复方氨基酸(19)丙谷二肽注射液、克林霉素磷酸酯外用乳液、骨化二醇缓释胶囊、酒石酸布托啡诺鼻喷剂、雌二醇透皮喷雾剂、氘可来昔替尼片、醋酸格拉替雷注射液、普伐他汀钠片、盐酸丙卡特罗片、呋喹替尼胶囊、阿贝西利片、克林霉素阿达帕林过氧苯甲酰外用凝胶、盐酸罗匹尼罗片、甲氨蝶呤注射液、伊曲康唑口服液、复方氨基酸（15）双肽（2）注射液、尿素[14C]胶囊、阿糖胞苷注射液、依达拉奉口服混悬液、苯磺酸美洛加巴林口崩片等；仿制药参比制剂目录（第101批）

一致性评价

2026-01-26

·生物谷

Nat Med：临床试验表明口腔癌药物阿贝西利有望对抗侵袭性脑肿瘤

该试验是首个根据突变检测结果招募患者的全国性研究，并表示这项研究表明，为脑膜瘤患者开展基因组学驱动的试验是可行的，并且靶向治疗可能会改善具有特定基因突变患者的预后。由Alliance for Clinical Trials in Oncology领导的一项全国性临床试验发现，口服抗癌药阿贝西利（abemaciclib）可能会减缓具有特定基因突变的侵袭性脑膜瘤患者的肿瘤生长。这项关于Alliance A071401试验的主要分析结果发表在《自然-医学》杂志上。脑膜瘤是生长在包围大脑和脊髓的膜中的肿瘤，是最常见的原发性脑肿瘤。虽然大多数是良性或可治疗的，但那些具有如NF2等基因突变和CDK通路改变的侵袭性脑膜瘤可能是致命的。对于那些脑膜瘤被认为是癌性、且在手术和放疗后复发或继续生长的患者来说，治疗选择极为有限。 "复发或进展性高级别脑膜瘤患者历来治疗选择非常少，之前大多数药物治疗试验的结果都令人失望，"资深作者、麻省总医院布莱根癌症中心神经肿瘤学家、Alliance神经肿瘤学委员会联合主席Priscilla Brastianos医学博士说。 Brastianos博士指出，该试验是首个根据突变检测结果招募患者的全国性研究，并表示这项研究"表明，为脑膜瘤患者开展基因组学驱动的试验是可行的，并且靶向治疗可能会改善具有特定基因突变患者的预后。" Alliance A071401试验跟踪了患有2级或3级脑膜瘤、且其肿瘤携带NF2突变或CDK通路改变的患者。所有接受评估的患者之前都接受过手术、放疗或两者兼有。患者平均接受了九个周期的abemaciclib治疗，这是一种目前被批准用于某些乳腺癌的CDK抑制剂。在接受abemaciclib治疗的最初24名患者中，58% 的高级别肿瘤在开始治疗后的六个月内没有进展。该研究没有设立对照组，因为对于手术和放疗后的高级别肿瘤患者缺乏标准的治疗选择。然而，这些结果与之前的研究相比更具优势，之前的研究发现，平均只有0–29% 的2级或3级脑膜瘤患者在接受实验性治疗后的六个月内癌症没有进展。在Alliance A071401试验中，中位无进展生存期为10个月，中位总生存期为29个月。副作用与其他癌症患者服用CDK抑制剂的经历相似。常见副作用包括腹泻、疲劳、头痛和恶心/呕吐。大约四分之一的患者出现了可能与治疗相关的严重副作用（3级或4级）。 "我们为这些令人振奋的结果感到鼓舞，但为了改善这个研究不足的患者群体的治疗，我们仍有更多的工作要做，"Brastianos博士说。（生物谷Bioon.com）参考文献： Priscilla K. Brastianos et al, Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial, Nature Medicine (2026). DOI: 10.1038/s41591-025-04141-4.

临床2期临床结果

2026-01-26

·大毒师

乳腺癌治疗的新纪元

乳腺癌仍然是全球最常见的癌症，每年新增病例约230万例，死亡病例约67万例。虽然高收入国家的生存率持续提高，但由于筛查和先进疗法的普及程度有限，许多地区的预后仍然很差。好消息是，我们正步入乳腺癌研究和治疗领域最具活力的时期之一。 🔹激素受体阳性乳腺癌（约占70%） – CDK4/6抑制剂已显著改善治疗效果 –目前的骨干疗法: • Palbociclib（Ibrance）——辉瑞 • Ribociclib（Kisqali）——诺华 • Abemaciclib (Verzenio) –礼来公司 🔬新一代及后期疗法 •伊姆鲁司群 (Imlunestrant) –礼来公司研发的口服选择性雌激素受体降解剂 (SERD)，可降解雌激素受体，即使产生耐药性也有效 •吉瑞司群 (Giredestrant) –罗氏公司研发，旨在比早期疗法更彻底地阻断雌激素受体信号传导 •维普地孕群 (Vepdegestrant，ARV-471) – Arvinas 公司与辉瑞公司联合研发，采用 PROTAC技术，可物理性地从癌细胞中去除雌激素受体 •格达托利西布 (Gedatolisib) – Celcuity 公司研发，可阻断 PI3K 和 mTOR 通路，而这两个通路是耐药性的关键驱动因素 •伊纳沃利西布 (Inavolisib) –罗氏公司研发，高选择性 PI3Kα抑制剂，可提高生存率并改善耐受性新型口服SERD、PROTAC降解剂和PI3K/mTOR抑制剂正在靶向耐药性并延缓化疗 🔹 HER2阳性及HER2低表达乳腺癌 –抗体药物偶联物（ADC）如何重新定义治疗并推动早期治疗 •曲妥珠单抗德鲁替康（Enhertu）——阿斯利康 + 第一三共：将化疗药物直接递送至表达 HER2 的细胞——现已更早使用 •达托泊单抗德鲁替康（Dato-DXd）——阿斯利康 + 第一三共：靶向 TROP2——显示出优于标准化疗的生存获益 •帕妥珠单抗德鲁替康（HER3-DXd）——第一三共：在脑转移患者中显示出显著疗效 🧠抗体偶联药物 (ADC) 的独特之处在于：它们结合了精准靶向和强效有效载荷，从而降低脱靶毒性并提高疗效 – HER2低表达乳腺癌如今为何成为可治疗的疾病类别 🔹三阴性乳腺癌（TNBC）约占所有病例的 15%，但死亡病例却占比过高。 ✅已确立的治疗方案 •帕博利珠单抗 (Keytruda) –默克公司 •沙妥珠单抗 (Trodelvy) –吉利德科学公司 –一项发表于《新英格兰医学杂志》（NEJM）的重要一线治疗研究，有望成为新的治疗标准 –一线创新疗法对于侵袭性疾病患者的生存至关重要 🔹基因、细胞及免疫疗法 –细胞疗法、个性化mRNA癌症疫苗、溶瘤病毒、CAR-T细胞疗法和TIL疗法 • Bria-IMT（细胞免疫疗法）——BriaCell Therapeutics •个性化mRNA癌症疫苗——BioNTech •溶瘤病毒疗法——Oncolytics Biotech • CAR-T和TIL疗法——由City of Hope等中心主导 🧠不同之处：这些方法旨在训练或重编程免疫系统，而非直接攻击肿瘤。 🔹男性乳腺癌:男性乳腺癌约占所有病例的1%，但预后往往更差——这主要是由于诊断延迟和临床试验参与度低所致。 📌人们常常忽略的关键点： •大多数男性乳腺癌为激素受体阳性 •现有证据通常来自女性临床试验 •男性乳腺癌的基因风险检测（BRCA基因突变）历来不足越来越适用于男性的疗法 •他莫昔芬仍然是基石疗法 •芳香化酶抑制剂联合促性腺激素释放激素（GnRH）抑制剂的使用越来越普遍 • CDK4/6抑制剂（帕博西尼、瑞博西尼、阿贝西利）现已纳入指南 • PARP抑制剂对携带BRCA突变的男性患者有益 •新型口服选择性雌激素受体调节剂（SERD）（例如伊莫司群）已获批用于男性和绝经后女性 🧠重要意义：随着精准肿瘤学的发展，男性乳腺癌终于被视为一个独立的群体进行研究，而非被忽视——这是癌症研究领域迈向公平的重要一步。 🔹人工智能在乳腺癌领域的应用 –更早的检测、更智能的病理分析、更快的药物研发、更优化的试验设计以及远程患者监测 🔮未来关注点：抗体偶联药物（ADC）在一线治疗中的应用、循环肿瘤DNA（ctDNA）指导的治疗方案转换、个性化疫苗以及人工智能驱动的精准肿瘤学。 📌乳腺癌不再被视为单一疾病——创新正从多个方向同时涌现。 Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Bañuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026 Jan 22;394(4):354-366. doi: 10.1056/NEJMoa2508959. PMID: 41564397.

免疫疗法细胞疗法蛋白降解靶向嵌合体临床结果抗体药物偶联物

100 项与阿贝西利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10688	阿贝西利	L01XE50	DB12001

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
晚期乳腺癌	加拿大	Eli Lilly Canada, Inc.	2019-04-08
转移性乳腺癌	加拿大	Eli Lilly Canada, Inc.	2019-04-08
HR阳性HER2阴性淋巴结阳性乳腺癌	欧盟	Eli Lilly Nederland BV	2018-09-26
HR阳性HER2阴性淋巴结阳性乳腺癌	冰岛	Eli Lilly Nederland BV	2018-09-26
HR阳性HER2阴性淋巴结阳性乳腺癌	列支敦士登	Eli Lilly Nederland BV	2018-09-26
HR阳性HER2阴性淋巴结阳性乳腺癌	挪威	Eli Lilly Nederland BV	2018-09-26
HR阳性/HER2阴性乳腺癌	美国	Eli Lilly & Co.	2017-09-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
去势敏感前列腺癌	临床3期	美国	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	中国	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	日本	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	阿根廷	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	澳大利亚	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	比利时	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	巴西	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	加拿大	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	捷克	Eli Lilly & Co.	2022-04-14
去势敏感前列腺癌	临床3期	法国	Eli Lilly & Co.	2022-04-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SABCS2025	N/A	HR阳性HER2阴性淋巴结阳性乳腺癌辅助 HR+ \| HER2-	1,063	Abemaciclib 150 mg BID	鹹網襯憲製鹽製顧醖簾(鬱衊艱鑰積觸壓簾淵鏇) = 鏇膚夢選積積蓋襯網夢壓鹹憲夢糧窪範獵廠鏇 (憲衊築選範衊壓鏇鹹壓 ) 更多	积极	2025-12-12
				Abemaciclib 150 mg BID (No Dose reductions)	鹹網襯憲製鹽製顧醖簾(鬱衊艱鑰積觸壓簾淵鏇) = 選衊窪築製壓淵選艱願壓鹹憲夢糧窪範獵廠鏇 (憲衊築選範衊壓鏇鹹壓 ) 更多
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌 HR+/HER2−	199	Abemaciclib + Fulvestrant or Aromatase Inhibitor (Endocrine resistant (ER))	鏇築築廠鏇獵鏇鹹憲淵(願餘憲簾壓衊範糧糧選) = 範壓壓艱積構膚積廠鏇醖願鬱壓簾選獵願鏇遞 (糧鬱夢衊襯鹽壓夢鏇襯 ) 更多	积极	2025-12-12
				Abemaciclib + Fulvestrant or Aromatase Inhibitor (Endocrine-sensitive (ES))	鏇築築廠鏇獵鏇鹹憲淵(願餘憲簾壓衊範糧糧選) = 鹹簾顧衊構廠鹹壓廠廠醖願鬱壓簾選獵願鏇遞 (糧鬱夢衊襯鹽壓夢鏇襯 ) 更多
NCT04158362 (AMBRE, SABCS2025)	临床3期	一线 HR+ \| HER2-	180	Abemaciclib + ET (letrozole or fulvestrant ± OFS)	鹽蓋鹹簾範鏇願鬱齋構(齋築艱網鬱築製選範鹽) = 願醖範齋鏇範遞蓋鹹製鹹鹹鹹獵醖選襯網淵鬱 (襯願觸構夢窪範鏇獵獵 ) 更多	积极	2025-12-11
				CT (weekly paclitaxel or capecitabine)	鹽蓋鹹簾範鏇願鬱齋構(齋築艱網鬱築製選範鹽) = 淵餘窪餘鏇壓範憲襯壓鹹鹹鹹獵醖選襯網淵鬱 (襯願觸構夢窪範鏇獵獵 )
SABCS2025	N/A	HR阳性/HER2阴性乳腺癌辅助	714	Abemaciclib combined with an aromatase inhibitor	壓衊鹽糧鏇構廠艱獵觸(鬱獵範獵鹹網衊鑰齋醖) = 鑰構選網築衊艱簾餘糧構膚顧鏇觸構鏇衊顧遞 (鏇鏇築糧鬱網鹽簾鏇鹹 ) 更多	积极	2025-12-11
SABCS2025	N/A	男性乳腺肿瘤辅助 HR+ \| HER2-	13	Abemaciclib	鬱憲醖願鑰齋壓鑰壓憲(鑰醖糧淵顧衊壓淵憲壓) = 淵顧獵艱鹹廠淵獵積網衊鬱廠顧遞簾憲構襯顧 (鏇顧獵衊壓範製鹽選築 ) 更多	积极	2025-12-11
EMBER-3 (SABCS2025)	临床3期	ER阳性/HER2阴性乳腺癌 ESR1 mutations	635	Imlunestrant	願繭製齋積醖遞鬱構淵(鑰顧壓襯蓋餘鬱壓廠築) = 獵餘選襯醖襯鑰糧觸蓋築鹽鹽艱襯窪蓋窪獵蓋 (築窪蓋築糧夢製範鹽鬱 ) 更多	积极	2025-12-11
				Standard Endocrine Therapy (SOC ET)	願繭製齋積醖遞鬱構淵(壓膚鏇網構艱製醖鏇獵) = 衊鬱繭鹽鹽積獵觸鏇襯觸蓋餘願積夢簾製選糧 (廠製鹹餘艱淵淵遞顧選 )
SABCS2025	N/A	HR阳性乳腺癌 HR+ \| HER2-	30	Abemaciclib monotherapy	蓋網壓構蓋淵鹽艱淵壓(糧願積襯憲積齋構築觸) = 鏇壓窪顧簾鏇願襯鹽鹹壓憲壓鏇鹹鏇觸鏇簾鹹 (夢鏇鑰鹹選膚鑰構蓋顧 ) 更多	积极	2025-12-10
NCT06001762 (TRADE, SABCS2025)	临床2期	HR阳性/HER2阴性乳腺癌辅助 HR+ \| HER2-	89	Abemaciclib + Abemaciclibnhibitor (HR+/HER2- early breast cancer)	廠窪膚鬱選獵襯餘構選(鏇廠餘顧餘蓋襯製簾醖) = 淵築顧鑰醖製築淵積糧壓顧淵醖壓廠鑰壓製憲 (鹽艱網製憲鏇蓋襯鬱衊 ) 更多	积极	2025-12-10
SABCS2025	N/A	早期乳腺癌辅助	146	Abemaciclib combined with endocrine therapy (Obese (≥30))	築襯製簾憲範蓋製製鹽(鏇鬱選構窪鑰襯衊齋襯) = 醖憲廠網鹽簾膚艱範選糧獵膚繭積鬱獵鬱範繭 (構廠構醖艱鹽醖憲醖鬱 ) 更多	积极	2025-12-10
				Abemaciclib combined with endocrine therapy (Non-Overweight (<25))	築襯製簾憲範蓋製製鹽(鏇鬱選構窪鑰襯衊齋襯) = 窪顧製餘選網構齋築網糧獵膚繭積鬱獵鬱範繭 (構廠構醖艱鹽醖憲醖鬱 ) 更多
SABCS2025	N/A	辅助 HR+ \| HER2-	189	Abemaciclib plus endocrine therapy	選繭夢築顧簾艱網淵遞(艱鹹獵鹹選鹹艱積餘繭) = 壓蓋窪遞襯窪壓顧蓋築鹽觸醖衊鹹壓網衊繭鹹 (襯蓋繭淵蓋餘衊網淵壓 ) 更多	积极	2025-12-10